Captain T Cell GmbH

Captain T Cell is advancing next-generation TCR-T cell therapies to overcome the limitations of immunotherapy in solid tumors. Its proprietary genetic “toolbox” enables T cells to achieve complete responses in preclinical models at a fraction of the dose used by competitors, unlocking automated, scalable manufacturing at significantly lower cost. With a best-in-class autologous program quickly approaching the clinic and a first-in-class allogeneic “off-the-shelf” platform showing complete responses in preclinical models, Captain T Cell is well-positioned to deliver impactful therapies. Backed by a combination of private investment and significant non-dilutive funding, the company offers a potentially game-changing approach in a rapidly growing market.